South San Francisco, United States
Anesiva, founded in 1999, is a late-stage biopharmaceutical company based in the United States. The company is primarily focused on establishing a leadership position in the development and commercialization of innovative pharmaceutical products for pain management.
Operating within the Biotechnology, Health Care, and Health and Wellness industries, Anesiva is dedicated to addressing unmet needs in pain management, which remains a critical area in the biopharmaceutical sector. Despite the absence of a catchy slogan to encapsulate its mission, its long-term presence in the market underscores a commitment to its foundational goals.
Anesiva last received a $2.00M investment through a Post-IPO Debt on 04 June 2009. The details of the investors involved in this round remain undisclosed. While further financial support may be necessary for continued growth and development, the company's strategic focus positions it well to capitalize on emerging opportunities and trends in pain management innovation.
Interventional Spine and Pain Center
